Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 11Endocrine 5NET 4Gastrointestinal 4Thoracic 1Head & Neck 1CNS 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 180Cisplatin 157Radiotherapy 78Carboplatin 71Radiotherapy, Intensity-Modulated 69Cetuximab 66Magnetic Resonance Spectroscopy 64Nivolumab 63Paclitaxel 52Docetaxel 50Specimen Handling 45Radiation 35Gemcitabine 33Fluorouracil 31Surveys and Questionnaires 28Biopsy 27toripalimab 26Drug Therapy 26Platinum 25Surgical Procedures, Operative 24Standard of Care 231,2-diaminocyclohexaneplatinum II citrate 23cemiplimab 22atezolizumab 21Capecitabine 20Ipilimumab 19Chemoradiotherapy 19durvalumab 18Taxes 17Immune Checkpoint Inhibitors 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lutetium × Head & Neck × 1 year × Clear all
NCT07274852 2026-01-06

A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1 Recruiting
22 enrolled
BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡